首页 News 正文

On September 14th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: CRDA) has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment of unresectable or metastatic melanoma. This approval changes the indication for melanoma in the product manual from "Pembrolizumab is suitable for the treatment of unresectable or metastatic melanoma that has failed first-line treatment" to "Pembrolizumab is suitable for the treatment of unresectable or metastatic melanoma".
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

小瓜虫 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    1